Literature DB >> 20435189

Increased risk for coronary heart disease after avascular necrosis of femoral head: A 3-year follow-up study.

Jiunn-Horng Kang1, Herng-Ching Lin.   

Abstract

BACKGROUND: Although pathomechanisms of avascular necrosis (AVN) of the femoral head are not well-known, vascular and coagulation abnormalities have been proposed as hypotheses. We propose that the pathomechanisms of AVN could also involve the cardiovascular system. This study explores the risk of coronary heart disease (CHD) after AVN, through a population-based case-control approach.
METHODS: We identified 1,450 patients with AVN as the study group and randomly selected 7,250 patients as the comparison group. Each patient was individually tracked for 3 years to identify all who developed CHD during the follow-up period. Cox proportional hazards regressions were performed to calculate the hazard ratios (HRs) of CHD for the 2 groups.
RESULTS: In total, 90 patients (6.21%) from the study group and 295 patients (4.07%) from the comparison group developed CHD during the follow-up period. Compared with patients in the comparison group, the HR for CHD among patients with AVN was 1.43 (95% CI 1.10-1.86, P = .002), after adjusting for geographic variables and cardiovascular risk factors. Among males, the adjusted HR for CHD was 1.65 (95% CI 1.20-2.27, P < .001). For patients <65 years old with AVN, the adjusted HR for CHD was 1.42 (95% CI 1.02-1.98, P = .021). There was no significant difference in the HR for CHD among females with AVN and patients > or =65 years old.
CONCLUSION: The incidence of CHD in the 3 years after AVN is significantly higher than in the general population. 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20435189     DOI: 10.1016/j.ahj.2010.02.020

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

1.  National trends and in hospital outcomes for total hip arthroplasty in avascular necrosis in the United States.

Authors:  William Mayers; Brian Schwartz; Aaron Schwartz; Vincent Moretti; Wayne Goldstein; Ritesh Shah
Journal:  Int Orthop       Date:  2016-01-05       Impact factor: 3.075

2.  Cardiovascular and Cerebrovascular Events Are Associated With Nontraumatic Osteonecrosis of the Femoral Head.

Authors:  Pei-Hsun Sung; Yao-Hsu Yang; Hsin-Ju Chiang; John Y Chiang; Chi-Jen Chen; Hon-Kan Yip; Mel S Lee
Journal:  Clin Orthop Relat Res       Date:  2018-04       Impact factor: 4.176

Review 3.  COVID-19 Pandemic: Cardiovascular Complications and Future Implications.

Authors:  Dhrubajyoti Bandyopadhyay; Tauseef Akhtar; Adrija Hajra; Manasvi Gupta; Avash Das; Sandipan Chakraborty; Ipsita Pal; Neelkumar Patel; Birendra Amgai; Raktim K Ghosh; Gregg C Fonarow; Carl J Lavie; Srihari S Naidu
Journal:  Am J Cardiovasc Drugs       Date:  2020-08       Impact factor: 3.571

Review 4.  High prevalence of prothrombotic abnormalities in multifocal osteonecrosis: description of a series and review of the literature.

Authors:  Jose A Gómez-Puerta; Pilar Peris; Joan Carles Reverter; Gerard Espinosa; Angeles Martinez-Ferrer; Ana Monegal; Juan Monteagudo; Dolors Tàssies; Nuria Guañabens
Journal:  Medicine (Baltimore)       Date:  2013-11       Impact factor: 1.889

5.  Prevalence of Nontraumatic Osteonecrosis of the Femoral Head and its Associated Risk Factors in the Chinese Population: Results from a Nationally Representative Survey.

Authors:  De-Wei Zhao; Mang Yu; Kai Hu; Wei Wang; Lei Yang; Ben-Jie Wang; Xiao-Hong Gao; Yong-Ming Guo; Yong-Qing Xu; Yu-Shan Wei; Si-Miao Tian; Fan Yang; Nan Wang; Shi-Bo Huang; Hui Xie; Xiao-Wei Wei; Hai-Shen Jiang; Yu-Qiang Zang; Jun Ai; Yuan-Liang Chen; Guang-Hua Lei; Yu-Jin Li; Geng Tian; Zong-Sheng Li; Yong Cao; Li Ma
Journal:  Chin Med J (Engl)       Date:  2015-11-05       Impact factor: 2.628

6.  Simultaneous bilateral minimally invasive total hip arthroplasty: A comprehensive review of the literature.

Authors:  Michael-Alexander Malahias; Kulapat Chulsomlee; Fritz Thorey
Journal:  Orthop Rev (Pavia)       Date:  2018-09-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.